Patients are being asked to participate in this study because they have a cancer in their
blood, Fanconi's Anemia, or have been unsuccessfully treated for bone marrow failure such as
Aplastic Anemia or Paroxysmal Nocturnal Hemoglobinuria. Any of these conditions could benefit
from an allogeneic stem cell transplant using a donor that is related to the patient.
Stem cells are created in the bone marrow. They grow into different types of blood cells that
the patient needs, including red blood cells, white blood cells, and platelets. In a
transplant, the patient's own stem cells are killed and then replaced by stem cells from the
donor.
Usually, patients are given very strong doses of chemotherapy prior to receiving a stem cell
transplant. However, because of the patient's condition, they have a high risk of
experiencing life-threatening treatment-related side-effects. Recently, some doctors have
begun to use chemotherapy that does not cause as many side-effects before patients receive a
transplant.
This research study adds CAMPATH 1H to a low-dose chemotherapy regimen, followed by an
allogeneic stem cell transplantation. We want to see whether adding CAMPATH 1H to the
transplant medications helps in treating the disease. We also want to see whether there are
fewer life-threatening side-effects from the treatment. CAMPATH 1H is a drug that is still
being studied. CAMPATH 1H stays active in the body for a long time after patients receive it,
which means it may work longer at preventing graft-versus-host-disease (GvHD) symptoms.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Baylor College of Medicine
Collaborators:
Texas Children's Hospital The Methodist Hospital Research Institute The Methodist Hospital System